Astellas Pharma ends development of dust mite allergy vaccine

Astellas Pharma will book an impairment loss of just under USD 400m due to three less-than-successful drug programs. One of the programs, concerning a DNA vaccine against dust mite-induced allergic rhinitis, has now been terminated.

Photo: Kim Kyung-Hoon/Reuters/Ritzau Scanpix

Japanese Astellas Pharma has been less than fortunate when it comes to its clinical development programs.

On Friday, the company announced that it will book an impairment loss for three drug candidates in the fourth quarter of fiscal 2021/2022, a company press release reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs